

## CLL

*A. Condoluci, Bellinzona (Switzerland), et al.*

### [INTERNATIONAL PROGNOSTIC SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA \(IPS-A\)](#)

**Authors Conclusion from the abstract:** Among stage A CLL initially managed with active surveillance, the IPS-A allows to inform upfront patients, physicians and researchers about the likelihood of disease progression.

*K. Fischer, Cologne (Germany), et al.*

### [FIXED-DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES](#)

**Authors Conclusion from the abstract:** Fixed-duration VenG induced deep, high (